CASI Pharmaceuticals Inc (CASI)vsMerck & Company Inc (MRK)
CASI
CASI Pharmaceuticals Inc
$0.21
0.00%
HEALTHCARE · Cap: $4.26M
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 250880% more annual revenue ($67.38B vs $26.85M). MRK leads profitability with a 3.6% profit margin vs -184.0%. MRK earns a higher WallStSmart Score of 44/100 (D).
CASI
Avoid24
out of 100
Grade: F
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CASI.
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1095.0% — below average capital efficiency
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : CASI
The strongest argument for CASI centers on Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CASI
The primary concerns for CASI are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
CASI profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CASI carries more volatility with a beta of 0.89 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (44/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CASI Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · China
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?